Tags

Type your tag names separated by a space and hit enter

Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration.
Scand J Gastroenterol Suppl. 1986; 119:166-9.SJ

Abstract

We have recently obtained encouraging short-term results after a single subcutaneous injection of the long-acting somatostatin analogue SMS 201-995 in acromegalic patients. Increased growth hormone (GH) levels may be involved in the pathogenesis of proliferative retinopathy in type I diabetes mellitus. In this study we thus investigated the effect of 3 X 50 micrograms SMS 201-995 daily on the metabolic control and hormone secretion of eight type I diabetics over a 3-day period. GH levels decreased by 32% (p less than 0.05) and somatomedin C levels by 31% (p less than 0.01) on the 3rd day of treatment compared with a control day. The insulin requirements during conventional subcutaneous insulin therapy were reduced by 28% (p less than 0.01) in seven patients without deterioration of metabolic control (mean blood glucose levels, 153.8) versus 154.7 mg/dl). Triiodothyronine, thyroxine, glucagon, prolactin, luteinizing hormone and follicle-stimulating hormone showed no significant changes. We conclude that SMS 201-995 could be an excellent tool for further clinical investigation and therapy of diabetic vascular complications.

Authors

Plewe G
No affiliation info available
Nölken G
No affiliation info available
Krause U
No affiliation info available
del Pozo E
No affiliation info available
Beyer J
No affiliation info available

MeSH

AdultBlood GlucoseClinical Trials as TopicDiabetes Mellitus, Type 1Drug Administration ScheduleFemaleGrowth HormoneHumansInsulin-Like Growth Factor IMaleOctreotideSomatostatin

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

2876502

Citation

Plewe, G, et al. "Somatostatin Analogue SMS 201-995 in Type I Diabetes Mellitus. Initial Experience After Repeated Administration." Scandinavian Journal of Gastroenterology. Supplement, vol. 119, 1986, pp. 166-9.
Plewe G, Nölken G, Krause U, et al. Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration. Scand J Gastroenterol Suppl. 1986;119:166-9.
Plewe, G., Nölken, G., Krause, U., del Pozo, E., & Beyer, J. (1986). Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration. Scandinavian Journal of Gastroenterology. Supplement, 119, 166-9.
Plewe G, et al. Somatostatin Analogue SMS 201-995 in Type I Diabetes Mellitus. Initial Experience After Repeated Administration. Scand J Gastroenterol Suppl. 1986;119:166-9. PubMed PMID: 2876502.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration. AU - Plewe,G, AU - Nölken,G, AU - Krause,U, AU - del Pozo,E, AU - Beyer,J, PY - 1986/1/1/pubmed PY - 1986/1/1/medline PY - 1986/1/1/entrez SP - 166 EP - 9 JF - Scandinavian journal of gastroenterology. Supplement JO - Scand J Gastroenterol Suppl VL - 119 N2 - We have recently obtained encouraging short-term results after a single subcutaneous injection of the long-acting somatostatin analogue SMS 201-995 in acromegalic patients. Increased growth hormone (GH) levels may be involved in the pathogenesis of proliferative retinopathy in type I diabetes mellitus. In this study we thus investigated the effect of 3 X 50 micrograms SMS 201-995 daily on the metabolic control and hormone secretion of eight type I diabetics over a 3-day period. GH levels decreased by 32% (p less than 0.05) and somatomedin C levels by 31% (p less than 0.01) on the 3rd day of treatment compared with a control day. The insulin requirements during conventional subcutaneous insulin therapy were reduced by 28% (p less than 0.01) in seven patients without deterioration of metabolic control (mean blood glucose levels, 153.8) versus 154.7 mg/dl). Triiodothyronine, thyroxine, glucagon, prolactin, luteinizing hormone and follicle-stimulating hormone showed no significant changes. We conclude that SMS 201-995 could be an excellent tool for further clinical investigation and therapy of diabetic vascular complications. SN - 0085-5928 UR - https://www.unboundmedicine.com/medline/citation/2876502/Somatostatin_analogue_SMS_201_995_in_type_I_diabetes_mellitus__Initial_experience_after_repeated_administration_ DB - PRIME DP - Unbound Medicine ER -